Skip to content

This website is a third-party information service. It does not provide medical care or operate a treatment facility.

Cancer Biologic Trials

Minnesota

Cancer biologic therapy trials in Minnesota

78 cancer biologic therapy studies are recruiting participants at sites in 47 cities across Minnesota as of November 18, 2026, according to ClinicalTrials.gov.

Call (888) 343-5902
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

Browse Minnesota by city

Cities with the most studies recruiting right now.

Every Minnesota city with a recruiting study

By research area: Lymphoma (32), Lung Cancer (22), Breast Cancer (11), Melanoma (7), Pancreatic Cancer (3), Prostate Cancer (3).

Minneapolis (48), Rochester (39), Duluth (25), Deer River (23), Hibbing (23), Sandstone (23), Virginia (23), Saint Paul (22), Coon Rapids (21), Edina (21), Saint Louis Park (21), Bemidji (14), Brainerd (14), Maplewood (12), Burnsville (10), Woodbury (10), Shakopee (9), Waconia (9), Robbinsdale (7), Saint Cloud (7), Maple Grove (6), Stillwater (5), Detroit Lakes (4), New Ulm (4), Worthington (4), Chaska (3), Fosston (3), Park Rapids (3), Thief River Falls (3), Aitkin (2), Baxter (2), Cambridge (2), Crosslake (2), Ely (2), International Falls (2), Mankato (2), Monticello (2), Moose Lake (2), Pequot Lakes (2), Pine River (2), Princeton (2), Staples (2), Willmar (2), Wyoming (2), Albert Lea (1), Fridley (1), Marshall (1).

The number after each city is how many studies have a recruiting site there. A study with sites in several cities is counted in each one.

Breast cancer: recently updated in Minnesota

Basic details from each study's public record (the 12 most recently updated of 78). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

    • Phase 2
    • All ages
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Recruiting in
    Bemidji · Coon Rapids · Deer River · and 11 more U.S. locations
    Registry record
    NCT05564377 · updated
  2. Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Recruiting in
    Saint Louis Park
    Registry record
    NCT06393374 · updated

Source: ClinicalTrials.gov. Data processed . See every breast cancer study recruiting in Minnesota on ClinicalTrials.gov.

Lung cancer: recently updated in Minnesota

  1. Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Recruiting in
    Bemidji · Brainerd · Coon Rapids · and 9 more U.S. locations
    Registry record
    NCT06498635 · updated
  2. Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Summit Therapeutics
    Recruiting in
    Duluth · Minneapolis · Saint Paul
    Registry record
    NCT06767514 · updated
  3. Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Recruiting in
    Brainerd · Coon Rapids · Deer River · and 9 more U.S. locations
    Registry record
    NCT07388524 · updated
  4. Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Recruiting in
    Minneapolis
    Registry record
    NCT06422143 · updated
  5. Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Recruiting in
    Bemidji · Burnsville · Coon Rapids · and 14 more U.S. locations
    Registry record
    NCT04267848 · updated

Source: ClinicalTrials.gov. Data processed . See every lung cancer study recruiting in Minnesota on ClinicalTrials.gov.

Prostate cancer: recently updated in Minnesota

  1. Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Recruiting in
    Deer River · Duluth · Edina · and 8 more U.S. locations
    Registry record
    NCT03866382 · updated

Source: ClinicalTrials.gov. Data processed . See every prostate cancer study recruiting in Minnesota on ClinicalTrials.gov.

Melanoma: recently updated in Minnesota

  1. BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Recruiting in
    Bemidji · Brainerd · Burnsville · and 18 more U.S. locations
    Registry record
    NCT05136196 · updated

Source: ClinicalTrials.gov. Data processed . See every melanoma study recruiting in Minnesota on ClinicalTrials.gov.

Lymphoma: recently updated in Minnesota

  1. Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

    • Phase 2
    • Up to 365 days
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Recruiting in
    Minneapolis
    Registry record
    NCT06317662 · updated
  2. Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Recruiting in
    Brainerd · Burnsville · Coon Rapids · and 11 more U.S. locations
    Registry record
    NCT06337318 · updated
  3. A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Recruiting in
    Marshall
    Registry record
    NCT05947851 · updated

Source: ClinicalTrials.gov. Data processed . See every lymphoma study recruiting in Minnesota on ClinicalTrials.gov.

Ask about studies in Minnesota

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 18, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded. This site lists only studies that test a biologic, such as a vaccine, an antibody, or a cell or gene therapy, as each study is coded in the registry.

Cancer Biologic Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 343-5902

or send a short form

How should we reach you?

Call